Grifols (GRFS) Total Debt Growth (3y) (2012 - 2025)
Grifols (GRFS) Total Debt Growth (3y) (2012 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Total Debt Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
31.94% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
1.29% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
1.29% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
3.15% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
16.90% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-2.37% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
-4.22% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
21.55% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Grifols |
- |
- |
- |
0.60% |
| Date | Value |
|---|
| Dec 31, 2025 |
0.60% |
| Dec 31, 2024 |
4.31% |
| Dec 31, 2023 |
-50.76% |
| Dec 31, 2022 |
351.91% |
| Dec 31, 2021 |
334.86% |
| Dec 31, 2020 |
6.30% |
| Dec 31, 2019 |
22.25% |
| Dec 31, 2018 |
-72.68% |
| Dec 31, 2017 |
8.66% |
| Dec 31, 2016 |
-74.74% |
| Dec 31, 2015 |
12.48% |
| Dec 31, 2014 |
9.08% |
| Dec 31, 2013 |
47.07% |
| Dec 31, 2012 |
44.40% |
